Filter News

Watson Pharmaceuticals, Inc. Receives FDA Approval For Mint Flavor Nicotine Gum

Published: Aug 03, 2004

CORONA, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it has received approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for nicotine polacrilex gum, mint flavor, in the 2 and 4 mg strengths.

Nicotine polacrilex gum, mint flavor, is the generic version of GlaxoSmithKline Consumer Healthcare's Nicorette(R) Mint gum, which is used as an aid to smoking cessation. The Company expects the product to be shipped by the end of the third quarter. For the 12-months ending June 2004, Nicorette(R) Mint gum had sales of approximately $75 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com/.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing, market acceptance of and demand for Watson's products, and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2003 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2004.

Nicorette(R) is a registered trademark of GlaxoSmithKline Consumer Healthcare, L.P.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.

CONTACT: Investors, Patty Eisenhaur, +1-909-493-5611, or Media, ChrisEso, +1-909-493-4013, both of Watson Pharmaceuticals, Inc.

Back to news